Clinical Evaluation of Cefoxitin in Respiratory Tract Infections

Cefoxitin was administered to a total of 66 patients with various respiratory tract infections and the Cefoxitin was administered to a total of 66 patients with various respiratory tract infections and thefollowing results were obtained: 1) Out of 55 patients who were clinically evaluated, 42 patients (76.4%) showed excellent and goodresponses. 2) The efficacy rate classified by diagnosis was 84.6% for primary pneumonia, 68.8% for secondarypneumonia and 69.2% for acute exacerbation of chronic bronchial tract infection. 3) The efficacy rate classified by severity of illness was 90.9% for mild cases, 76.3% for moderatecases and 50.0% for severe cases. 4) The efficacy rate classified by age was 82.8% for patients younger than 69 years and 69.2% forpatients older than 70 years. 5) Causative organisms were isolated in 13 patients. These organisms were eradicated in 10patients, decreased in number in one patient and replaced by other organisms in 2 patinens. In these 2patients normal flora was replaced by othr organisms during the course of treatment. The organisms thatemerged were P. aeruginosa (2 cases), E. agglomerans (1 case) and K. pneumoniae (1 case). 6) A total of 11 patients who failed to respond to other conventional antibiotic treatment weretreated with cefoxitin and seven patients (63.6%) showed excellent and good responses. 7) Out of 55 patients who were clinically evaluated, 3 patients failed to respond to cefoxitin. Thefirst patient was successfully treated with minocycline, the second with ceftizoxime and the third withcefotaxime. 8) Side effects were observed in 8 out of 63 patients. These were skin eruption (1), elevation ofSGOT (2), elevation of SGOT and BUN (1), elevation of BUN and creatinine (1), elevation of Al-p (1) andleukopenia (2).